Everest Medicines cracks open $451m Hong Kong IPO

biopharma_stocks_adobe_575x375.jpg
By Jonathan Breen
25 Sep 2020

Biopharmaceutical firm Everest Medicines has hit the road for its up to HK$3.5bn ($451m) Hong Kong IPO.

After pre-marketing the deal since the start of the week, the listing sponsors Bank of America and Goldman Sachs kicked off bookbuilding on Friday. The duo is leading a syndicate of seven banks.

Everest operates in China and emerging market in Asia Pacific, with a focus on ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial